Intelligence Brief — Life Sciences GTM
What moved in Life Sciences commercial markets this week. Named companies, specific numbers, and a play for each signal. Published Tuesday and Friday by MarlowIQ.
EQT agrees to take QIAGEN private for about 9.6 billion euros in cash.
EQT agreed on October 21 to acquire QIAGEN for about 9.6 billion euros, roughly 10.8 billion dollars. The offer is 46.50 euros per share, a 40.3% premium to the pre-speculation price. QIAGEN suspended its 2026 outlook alongside the deal. The same day it reported preliminary Q3 net sales of 548 million dollars and adjusted EPS of 0.65 dollars.
A second mid-cap tools peer is changing owners in 2026, after Bio-Techne shareholders approved the Merck KGaA merger. Private equity owners typically review portfolio, pricing and channel economics in the first year. Sample prep, PCR and syndromic testing customers will reassess supplier continuity, which opens accounts to competitors.
Sample prep, PCR and molecular diagnostics commercial teams should activate their top 25 shared QIAGEN accounts this quarter with multi-year supply and pricing terms. The window is before EQT discloses its operating plan and customers lock 2027 budgets.
Samsung Biologics raises 2026 growth guidance to 20% while Q3 operating profit grows only 1%.
Samsung Biologics reported Q3 2026 revenue of KRW 1,490.3 billion, up from KRW 1,257.5 billion, an 18.5% increase. Operating profit was KRW 640.1 billion versus KRW 633.5 billion a year earlier. Plants 1 to 4 ran at full capacity, Plant 5 is ramping, and the acquired Rockville, Maryland site contributed revenue for the first time. Cumulative contract orders exceed 21.9 billion dollars.
Operating margin fell from about 50% to about 43% as new capacity came online. Samsung now has U.S. manufacturing and Plant 5 volume to fill. That combination usually means sharper pricing in large-molecule tenders, which pressures other biologics CDMOs. Bioprocessing consumables and equipment suppliers gain a growing account.
Biologics CDMOs with active 2027 large-molecule tenders should reprice and sharpen U.S.-capacity positioning against Samsung Biologics before year-end awards. Bioprocessing suppliers should engage Samsung Plant 5 and Rockville procurement this quarter while ramp volumes are set.
mIQ (0–100): our composite score of how ready an account is to buy.
Three accounts moved in mIQ this week on confirmed procurement and pipeline signals.
Full access shows mIQ scores for all 970+ accounts and the ranked opportunity board.
3 signals this week — each with a named play and specific timing.
Full access: mIQ scores on 970+ accounts, active clinical trial pipeline, and every competitor baseline — updated weekly.
Request full access →1 more signal in this brief.
MarlowIQ is in private preview. Request access to read every signal and receive Tuesday and Friday briefs in your inbox.
By invitation — design partners only.
Go deeper on any signal — Ask Marlow →